fluticasone and Skin-Neoplasms

Vitiligo is an acquired skin disorder caused by the disappearance of pigment cells from the epidermis that gives rise to well defined white patches which are often symmetrically distributed. The lack of melanin pigment makes the lesional skin more sensitive to sunburn. Vitiligo can be cosmetically disfiguring and it is a stigmatizing condition, leading to serious psychologic problems in daily life. It occurs worldwide in about 0.5% of the population and it occurs as frequently in males as it does in females. The cause is unknown, but might involve genetic factors, autoimmunity, neurologic factors, toxic metabolites, and lack of melanocyte growth factors. Since a causative (gene) treatment is not (yet) available, current modalities are directed towards stopping progression and to achieving repigmentation in order to repair the morphology and functional deficiencies of the depigmented skin areas. Many treatments have been used for some time; however; there are some new developments: narrowband ultraviolet (UV) B (311 nm) therapy, the combination of corticosteroid cream + UVA therapy, and the transplantation of autologous pigment cells in various modalities. In widespread vitiligo, residual pigment can be removed by depigmentation agents. Sunscreens, camouflage products, and good guidance may help the patient cope better with the disease.

Topics: Androstadienes; Anti-Inflammatory Agents; Antioxidants; Autoimmune Diseases; Catalase; Combined Modality Therapy; Dermatologic Agents; Evidence-Based Medicine; Fluticasone; Growth Substances; Humans; Laser Therapy; Lipoproteins; Melanocytes; Patient Selection; Practice Guidelines as Topic; PUVA Therapy; Skin Neoplasms; Skin Transplantation; Treatment Outcome; Ultraviolet Therapy; Vitiligo

Topics: Administration, Inhalation; Adrenergic beta-Agonists; Aged; Aged, 80 and over; Albuterol; Androstadienes; Anti-Inflammatory Agents; Antineoplastic Agents; Bronchial Diseases; Bronchodilator Agents; Constriction, Pathologic; Delayed-Action Preparations; Drug Administration Schedule; Female; Fluticasone; Forced Expiratory Volume; Hemangioendothelioma; Humans; Infusions, Intravenous; Injections, Intralesional; Interleukin-2; Male; Middle Aged; Premedication; Salmeterol Xinafoate; Skin Neoplasms